浙江向日葵大健康科技股份有限公司 关于独立董事任期即将届满离任的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 证券代码：300111 证券简称：向日葵 公告编号：2023—050 特此公告。 浙江向日葵大健康科技股份有限公司董事会 2023年8月14日 浙江向日葵大健康科技股份有限公司（以下简称"公司"）董事会于 2023 年 8 月 14 日收到公司独立董事王永乐先生提交的书面辞职报告。根据《上市公 司独立董事规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上 市公司规范运作》等有关规定，独立董事在同一家上市公司连续任职时间不得超 过六年，王永乐先生因连任公司独立董事时间将满六年，故申请辞去公司独立董 事及相应的董事会专门委员会职务，辞职后将不再担任公司任何职务。截至本公 告日，王永乐先生未持有公司股份，不存在应当履行而未履行的承诺事项。 王永乐先生的离任将导致公司独立董事的人数不足董事会人数的三分之一， 根据《公司法》《上市公司独立董事规则》《深圳证券交易所上市公司自律监管指 引第 2 号——创业板上市公司规范运作》以及《公司章程》等 ...

股票代码：300111 股票简称：向日葵 浙江向日葵大健康科技股份有限公司 投资者关系活动记录表 编号：2023002 √特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活动 □新闻发布会 □路演活动 类别 □现场参观 □其他（请文字说明其他活动内容） 参与单位名称及 人员姓名 上海喜世润投资 张亚北；国泰基金 孙朝晖；秋阳投资 郑捷 时间 2023 年 6 月 19 日下午 15:00-17:30 地点 贝得药业会议室 公共关系和投资者关系管理总监：张冬云；董事会秘书：李岚； 上市公司接待人 贝得药业副总裁：黄群；浙江隆向副总经理：仲春华 员姓名 1、公司 2023 年部署的重点工作包括哪些方面？ 答：2023 年，公司将紧紧围绕发展战略和年度经营计划， 重点部署以下三方面工作：其一，进一步夯实医药主业。产品 研发方面，公司根据自身特点结合市场需求积极开展新产品选 择与立项，丰富公司现有产品矩阵，通过外部引进、合作与自 主开发等多种方式，确保在研产品的快速生产转化；市场拓展 投资者关系活动 方面，在稳固现有市场的基础上，加大国内外市场拓展力度， 主要内容介绍 积极参加全国和各省地区的招标采购 ...

Group 1: Company Advantages in the Photovoltaic Industry - The company has over 10 years of experience in the photovoltaic industry, which provides a rich resource advantage for controlling product costs and enhancing profitability [1][2] - The management team possesses extensive experience in photovoltaic project construction and operation, enabling quick recruitment of skilled personnel [2] - The company has established mature plans for equipment selection and capacity planning, ensuring efficient production processes [2] Group 2: Financial Performance and Impact of New Investments - The company predicts that investments in photovoltaic projects will not adversely affect its cash flow or disrupt existing operations, maintaining a balanced financial outlook [2] - The net profit for the first three quarters of the previous year was negative, primarily due to domestic procurement policies and rising costs, leading to a decrease in gross margin [3][4] - Foreign sales revenue increased by 71.12% year-on-year, driven by demand recovery in markets like South Korea and India [3] Group 3: Strategic Focus and Future Plans - The company is actively participating in the photovoltaic industry, which is supported by national policies and has a promising growth outlook [4][5] - The company has chosen the TOPCon battery technology for its advantages in efficiency and cost-effectiveness compared to other technologies [4] - Future strategies will focus on the pharmaceutical health sector, advanced manufacturing, and high-tech industries, aiming to create a robust industrial cluster [5]

Financial Performance - The company's operating revenue for 2022 was RMB 335.86 million, an increase of 12.97% compared to the previous year[5]. - Operating profit decreased to RMB 5.91 million, a decline of 89.15% year-on-year[5]. - Net profit attributable to shareholders was a loss of RMB 1.14 million, down 102.13% from the previous year[5]. - The subsidiary, Beid Pharmaceutical, saw a significant decline in net profit despite a 13.14% increase in main business revenue, primarily due to price reductions from domestic procurement policies and rising costs[5]. - The gross margin for the pharmaceutical products decreased by 15.01% year-on-year[5]. - The net cash flow from operating activities decreased by 75.66% to ¥24,157,571.67 from ¥99,269,612.43 in the previous year[24]. - The basic earnings per share for 2022 was -¥0.001, down 102.08% from ¥0.048 in 2021[24]. - The company reported a significant decline in net profit after deducting non-recurring gains and losses, with a loss of ¥785,242.97 compared to a profit of ¥3,808,918.11 in 2021, marking a 120.62% decrease[24]. - The company's operating revenue for the reporting period was CNY 335.86 million, an increase of 12.97% year-on-year[54]. - The cost of goods sold rose to CNY 239.57 million, reflecting a year-on-year increase of 27.71%[54]. - The net profit attributable to the parent company decreased by 102.13% year-on-year, primarily due to price reductions from domestic procurement policies and rising costs[55]. Research and Development - Research and development expenses amounted to CNY 14.19 million, up 15.69% compared to the previous year[54]. - The number of R&D personnel increased by 15.87% to 73, with R&D personnel accounting for 24.75% of the total workforce[72]. - The R&D investment as a percentage of operating income was 4.23% in 2022, up from 4.13% in 2021[72]. - The company completed several key R&D projects aimed at product upgrades and cost reduction, which are expected to enhance market competitiveness[71]. - Research and development expenses increased by 20% to 150 million RMB, focusing on innovative health technology solutions[186]. Market Position and Strategy - The company is positioned in the pharmaceutical manufacturing industry, which is expected to face both challenges and opportunities due to ongoing reforms and policies in the healthcare sector[36]. - The company focuses on pharmaceutical formulations, with a strong emphasis on refining and strengthening its active pharmaceutical ingredients (APIs) for anti-infection and cardiovascular disease treatments[38]. - The company aims to expand its market share by leveraging overseas certifications in the US, Europe, Japan, and South Korea, while improving its marketing system and brand building[92]. - The company plans to enhance its product structure through new product selection and project initiation, while strengthening R&D capabilities and optimizing production processes[92]. - The company is actively responding to national policies promoting the green and low-carbon transformation of the API industry, focusing on improving preparation technology and waste treatment[39]. Governance and Compliance - The company reported a significant improvement in its governance structure, ensuring compliance with relevant laws and regulations, which enhances operational transparency and investor trust[102]. - The company has established a performance evaluation and incentive system linking management compensation to business performance, promoting accountability and transparency[103]. - The company has implemented a robust information disclosure system, ensuring timely and accurate communication with investors[104]. - The company has a clear organizational structure with independent operational capabilities across its various departments, enhancing operational efficiency[106]. - The company has committed to maintaining effective governance and timely decision-making to protect shareholder interests[126]. Environmental Management - The company has established a comprehensive environmental management system, complying with multiple environmental protection laws and standards[152]. - The company holds a valid pollution discharge permit, effective from October 28, 2022, to October 27, 2027[153]. - The wastewater treatment process includes multiple stages to ensure compliance with discharge standards, effectively reducing COD and nitrogen levels[155]. - The company has implemented an automatic online monitoring system for real-time tracking of wastewater discharge[156]. - The company is committed to continuous improvement in environmental management and pollution prevention measures[156]. Legal and Financial Obligations - The company is involved in ongoing litigation with Jiangsu Zhenfa New Energy Co., Ltd., with a claim amounting to 46,171,177.33 yuan, which includes interest calculated at the benchmark rate[197]. - The company has a contingent liability of up to 22 million yuan related to a guarantee obligation, which is expected to be settled within ten days after the conclusion of bankruptcy proceedings of a related party[198]. - The company has been ordered to pay 17,692,345.50 yuan to China Bank, with a deadline for payment set within ten days after the judgment becomes effective[198]. - The company is actively managing its debt and legal obligations to ensure future growth[200]. - The company has made significant progress in its financial obligations, with a focus on maintaining operational stability[200]. Shareholder Engagement - The company held multiple shareholder meetings with participation rates of 17.80% for the first extraordinary meeting and 17.78% for the annual meeting, indicating active shareholder engagement[108]. - The company has not engaged in any significant related party transactions that could compromise its operational independence[106]. - The company has committed to ensuring that the interests of the company and all shareholders are maintained[168]. - The company has established a commitment to ensure that the compensation system aligns with the execution of return measures[183]. - The company has confirmed that all commitments made are independently enforceable, and any invalidation of one will not affect the others[184].

Financial Performance - The company's revenue for Q1 2023 was CNY 61,283,853.74, a slight increase of 0.26% compared to CNY 61,125,009.58 in the same period last year[2] - The net loss attributable to shareholders was CNY -12,361,272.45, representing a significant increase of 77.28% compared to CNY -6,972,862.62 in Q1 2022[2] - The net loss for Q1 2023 was CNY 18,122,914.98, compared to a net loss of CNY 10,308,925.24 in Q1 2022, indicating a deterioration in financial performance[25] - The net profit attributable to the parent company for Q1 2023 was -12,361,272.45 CNY, compared to -6,972,862.62 CNY in the same period last year, reflecting a significant increase in losses[26] - The total comprehensive income attributable to the parent company was -12,432,318.45 CNY, up from -6,994,774.62 CNY year-over-year[26] Cash Flow - The net cash flow from operating activities was CNY -49,091,730.98, a decline from a positive 40,096,954.06 CNY in the previous year[28] - Operating cash inflow decreased by 47.51% year-on-year to ¥57,171,285.23 due to a reduction in cash received from sales[11] - Operating cash outflow increased by 54.39% year-on-year to ¥106,263,016.21 primarily due to higher cash payments for goods and services[11] - Cash inflows from operating activities totaled 57,171,285.23 CNY, down from 108,925,304.12 CNY in the same quarter last year[28] - Cash outflows from operating activities increased to 106,263,016.21 CNY, compared to 68,828,350.06 CNY in the previous year[28] - Cash flow from financing activities saw an inflow of ¥426,756,718.53, marking a 100% increase due to raised funds and bank loans[11] - The net cash flow from financing activities was 417,293,101.62 CNY, indicating strong capital inflow[29] Assets and Liabilities - Total assets increased by 59.16% to CNY 980,809,652.72 from CNY 616,248,544.88 at the end of the previous year[2] - Total liabilities increased to CNY 213,459,794.92 from CNY 201,412,272.64, representing an increase of about 6.2%[22] - The company's equity attributable to shareholders rose by 125.36% to CNY 644,066,847.79 from CNY 285,791,619.70[3] - Cash and cash equivalents increased to CNY 822,849,281.08 from CNY 454,856,833.80, indicating a growth of about 80.5%[22] - Short-term borrowings increased by 152.49% to CNY 76,457,459.46, mainly due to new bank loans[8] Operating Costs and Expenses - Operating costs increased by 16.67% to CNY 53,631,564.35, primarily due to an increase in product sales volume[9] - Total operating costs increased to CNY 78,233,428.53 from CNY 72,010,336.25, marking an increase of about 8.8% year-over-year[24] - Research and development expenses decreased by 12.37% to CNY 3,605,590.86 compared to CNY 4,114,429.00 in the same period last year[9] - Research and development expenses for the quarter were CNY 3,605,590.86, down from CNY 4,114,429.00, reflecting a decrease of approximately 12.3%[25] - The company reported a decrease in sales expenses to CNY 11,097,990.65 from CNY 14,724,457.50, a reduction of about 24.5%[25] Shareholder Information - Total number of common shareholders at the end of the reporting period was 69,226[13] - The largest shareholder, Wu Jianlong, holds 28.79% of shares, amounting to 370,630,131 shares, with 154,000,000 shares pledged[13] Investments and Projects - The company completed a fundraising of ¥375 million to improve financial conditions and enhance risk resistance capabilities[16] - The company approved the investment in the TOPCon battery product project during the board meeting on March 14, 2023[16] Cash and Cash Equivalents - Cash and cash equivalents increased from ¥233,191,064.97 at the beginning of the year to ¥597,304,719.70 by March 31, 2023[19] - The company reported cash and cash equivalents at the end of the period amounting to 565,524,317.15 CNY, a significant increase from 217,837,338.45 CNY at the end of the previous year[29]

证券代码：300111 证券简称：向日葵 公告编号：2023—041 参与方式一：在微信小程序中搜索"向日葵投资者关系"； 参与方式二：微信扫一扫以下二维码： 投资者依据提示，授权登入"向日葵投资者关系"小程序，即可参与交流。 出席本次网上说明会的人员有：公司董事长曹阳先生，董事、副总经理、财 务总监潘卫标先生，独立董事刘国华先生，董事会秘书李岚女士，保荐代表人周 祖运先生、张天宇先生。 浙江向日葵大健康科技股份有限公司 关于举行2022年度网上业绩说明会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 浙江向日葵大健康科技股份有限公司（以下简称"公司"）已于2023年4月 26日在巨潮资讯网（http://www.cninfo.com.cn/）上披露了《2022年年度报告》及 《2022年年度报告摘要》。 为便于广大投资者进一步了解公司2022年年度经营情况，公司定于2023年5 月11日（星期四）下午15:00-17:00在"向日葵投资者关系"小程序举行2022年度 业绩网上说明会。本次网上说明会将采用网络远程的方式举行，投资者可登陆 "向日葵投资者 ...

证券代码：300111 证券简称：向日葵 浙江向日葵光能科技股份有限公司 投资者关系活动记录表 编号：2016003 | --- | --- | --- | |----------------|--------------------------------|----------------------------------------------------| | | | | | 投资者关系活动 | ■ | 特定对象调研 □分析师会议 | | 类别 | □ 媒体采访 □业绩说明会 | | | | □新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 财通证券股份有限公司：张成 | | | 人员姓名 | | | | 时间 | 2016 年 4 月 28 | 日 | | 地点 | 公司一楼会议室 | | | 上市公司接待人 | | | | 员姓名 | 杨旺翔 | | | 投资者关系活动 | 1 、公司硅片产能 | 8800 万片、电池片产能 600MW 、组 | | 主要内容介绍 | 件产能 800MW | ，公司目前产能 ...

证券代码：300111 证券简称：向日葵 浙江向日葵光能科技股份有限公司 投资者关系活动记录表 编号：2016001 | --- | --- | --- | |----------------|----------------------------|------------------------------------------------------| | | | | | 投资者关系活动 | ■ | 特定对象调研 □分析师会议 | | 类别 | □ 媒体采访 □业绩说明会 | | | | □新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 太平洋证券股份有限公司：雷强、刘晶敏 | | 人员姓名 | 华泰证券股份有限公司：何昕 | | | 时间 | 2016 年 1 月 14 | 日 | | 地点 | 公司一楼会议室 | | | 上市公司接待人 | 杨旺翔 | | | 员姓名 | | | | 投资者关系活动 | 1 、光伏行业形势怎么样？ | | | 主要内容介绍 | | 国家能源局"十三五"的太阳能利用意见稿 ...

证券代码：300111 证券简称：向日葵 浙江向日葵光能科技股份有限公司 投资者关系活动记录表 编号：2016002 | --- | --- | --- | |----------------|-------------------------|-------------------------------------------------------------| | | | | | 投资者关系活动 | ■ | 特定对象调研 □分析师会议 | | 类别 | □ 媒体采访 □业绩说明会 | | | | □新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 长城国瑞证券有限公司：潘永乐、李志伟 | | 人员姓名 | | | | 时间 | 2016 年 3 月 23 | 日 | | 地点 | 公司一楼会议室 | | | 上市公司接待人 | | | | 员姓名 | 杨旺翔 | | | 投资者关系活动 | 1 、光伏行业趋势 | | | 主要内容介绍 | | 去年下半年增量较快，受电价调整因素， 2016 年 1 月 1 | ...

股票代码：300111 股票简称：向日葵 浙江向日葵大健康科技股份有限公司 投资者关系活动记录表 编号：2022001 | --- | --- | --- | |-------------------------|----------------------------------|------------------------------------------------------| | | □特定对象调研 □分析师会议 | | | | □媒体采访 | √业绩说明会 | | 投资者关系活动 | □新闻发布会 □路演活动 | | | 类别 | □现场参观 | | | | □其他 | （请文字说明其他活动内容） | | 参与单位名称及 人员姓名 | 网上投资者 | | | | 2022 年 5 月 11 日下午 | 15:00-17:00 | | 时间 | "向日葵投资者关系"小程序 | | | 地点 上市公司接待人 | | 董事长：曹阳先生，董事、副总经理、财务总监：潘卫标 | | 员姓名 | | 先生，独立董事：刘国华先生，董事会秘书：李岚女士 | | | 1、 2021 | 年度公司扣非净利润大幅下 ...